DeZwarteRidder schreef op 18 november 2019 16:11:
[...]
Conclusion: I'm waiting to see which way the share price moves ahead of next results
This is far from the best time to be buying Arrowhead. Investors who bought at the beginning of 2019 must be rubbing their hands in glee. But it could be that we have reached saturation point.
On the other hand, if RNAi drugs start to crush it in phase 3 clinical trials and are approved for commercialization, we could see Arrowhead stock disappear beyond the $100 mark.
Waiting until after the next set of results will mean losing out if they prove to be another catalyst for dramatic share price gain. Hence, I will be watching closely for signs of progress, and plan to invest, all being well, shortly before the next set of results, due on November 25th.